NEW YORK, September 21, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation
(NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN),
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc.
(NASDAQ: STEM). Free research report on Exelixis can be accessed at
https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite
ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average
declined 1.74%, to finish the day at 16,384.79, and the S&P 500
closed at 1,958.03, down 1.62%. The losses were broad based as
eight out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
Exelixis Inc.'s stock advanced 4.98%, to close the day at
$6.53. The stock recorded a trading
volume of 17.28 million shares, much above its three months average
volume of 6.94 million shares. Over the last one month and over the
past three months, Exelixis Inc.'s shares have surged 14.16% and
70.05%, respectively. Furthermore, the stock has rallied 353.47%
since the start of this year. The company's shares are trading
18.06% and 95.22% above their 50-day and 200-day moving averages,
respectively. Additionally, Exelixis Inc. has a Relative Strength
Index (RSI) of 61.93. Sign up and read the free notes on EXEL
at:
https://www.erionline.net/EXEL.pdf
On Friday, shares in XOMA Corp. recorded a trading volume of
9.65 million shares, higher than their three months average volume
of 5.86 million shares. The stock ended the day 5.31% lower at
$0.81. XOMA Corp.'s stock has
plummeted 2.41% in the last one month, 79.12% in the previous three
months and 77.44% on YTD basis. The company is trading below its
50-day and 200-day moving averages by 45.79% and 74.46%,
respectively. Furthermore, shares of XOMA Corp. have an RSI of
47.11. The complimentary notes on XOMA can be downloaded in PDF
format at:
https://www.erionline.net/XOMA.pdf
Enzon Pharmaceuticals Inc.'s stock closed Friday's session flat
at $1.01. The stock recorded a
trading volume of 0.25 million shares, below its three months
average volume of 1.16 million shares. Over the previous three
months and since the start of this year, Enzon Pharmaceuticals
Inc.'s shares have surged 18.33% and 50.74%, respectively. However,
the stock has declined 9.01% in the last one month. The company is
trading 21.39% above its 200-day moving average. Furthermore, Enzon
Pharmaceuticals Inc.'s stock traded at a PE ratio of 1.84 and has
an RSI of 49.25. Register for free on Equity Research Institute and
access the latest research on ENZN at:
https://www.erionline.net/ENZN.pdf
Peregrine Pharmaceuticals Inc.'s stock finished Friday's session
4.27% lower at $1.12. A total of 1.58
million shares were traded, which was above its three months
average volume of 1.11 million shares. Over the previous three
months and since the beginning of 2015, Peregrine Pharmaceuticals
Inc.'s shares have plummeted 20.00% and 19.42%, respectively. The
company's shares are trading below their 50-day and 200-day moving
averages by 7.41% and 16.13%, respectively. Peregrine
Pharmaceuticals Inc.'s stock has an RSI of 41.59. The complete
research on PPHM is available for free at:
https://www.erionline.net/PPHM.pdf
On Friday, shares in StemCells Inc. ended the session 1.92%
lower at $0.51. The stock reported a
trading volume of 0.69 million shares, below its three months
average volume of 1.09 million shares. Although, StemCells Inc.'s
shares have surged 18.60% in the last one month, it has lost 27.14%
in the previous three months and 45.74% on YTD basis. The company
is trading 10.39% above its 50-day moving average. Moreover, shares
of StemCells Inc. have an RSI of 53.72. Free in-depth research on
STEM is available at:
https://www.erionline.net/STEM.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net